- Home
- TIGR vs NVAX Comparison
TIGR vs NVAX Comparison
Compare TIGR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIGR | NVAX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TIGR | NVAX |
|---|---|---|
| Price | $8.01 | $8.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $14.20 | $10.78 |
| AVG Volume (30 Days) | 2.8M | ★ 5.9M |
| Earning Date | 03-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 328.15 | N/A |
| EPS | 0.82 | ★ 2.07 |
| Revenue | $489,538,356.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $79.26 | $58.91 |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | $9.73 | ★ $4.20 |
| Revenue Growth | ★ 76.50 | 20.27 |
| 52 Week Low | $6.38 | $5.01 |
| 52 Week High | $13.55 | $10.65 |
Technical Indicators
Market Signals| Indicator | TIGR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 52.89 |
| Support Level | $7.80 | $8.25 |
| Resistance Level | $8.65 | $9.28 |
| Average True Range (ATR) | 0.34 | 0.58 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 21.05 | 36.15 |
Price Performance
Historical ComparisonAbout TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.